紫杉醇是从红豆杉中分离出的一种复杂的次生代谢产物，已成为世界公认的强活性广谱抗癌药物。紫杉醇水溶性差，口服生物利用度低，传统注射剂采用聚氧乙烯蓖麻油作为助溶剂，导致过敏反应发生率较高，临床使用前需进行预脱敏处理。因此，紫杉醇非注射给药系统的研究非常活跃，表明临床上对紫杉醇非注射剂型的需求巨大。综述了紫杉醇非注射给药系统的研究进展，包括口服给药系统、阴道给药系统、透皮给药系统、植入释药系统、鼻腔给药系统和吸入给药系统，为今后的研究和临床应用提供参考。

Paclitaxel (PTX) is a complex secondary metabolite isolated from Taxus brevifolia, which widely used as chemotherapentic agent with a broad spectrum of actinity against cancer in the world. Its water solubility was poor and oral bioavailability was low. Cremophor-EL was used in traditional PTX injections to improve the solubility of PTX, and resulted in several adverse side effects such as severe hypersensitivity. Pre-desensitization treatment was needed before clinical use. Recently, a variety of non-injection drug delivery systems (DDS) of PTX have been developed. In this paper, the research progress of non-parenteral PTX was reviewed, including oral administration systems, vaginal administration systems, transdermal DDS, implantable DDS, transdermal DDS, intranasal administration and inhalation DDS, so as to provide references for future study and clinical applications.